Browse IRF1

Summary
SymbolIRF1
Nameinterferon regulatory factor 1
Aliases MAR; interferon regulatory factor-1; IRF-1; interferon regulatory factor 1 isoform +I9; interferon regulator ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm. Note=MYD88-associated IRF1 migrates into the nucleus more efficiently than non-MYD88-associated IRF1.
Domain PF00605 Interferon regulatory factor transcription factor
Function

Transcriptional regulator which displays a remarkable functional diversity in the regulation of cellular responses. These include the regulation of IFN and IFN-inducible genes, host response to viral and bacterial infections, regulation of many genes expressed during hematopoiesis, inflammation, immune responses and cell proliferation and differentiation, regulation of the cell cycle and induction of growth arrest and programmed cell death following DNA damage. Stimulates both innate and acquired immune responses through the activation of specific target genes and can act as a transcriptional activator and repressor regulating target genes by binding to an interferon-stimulated response element (ISRE) in their promoters. Its target genes for transcriptional activation activity include: genes involved in anti-viral response, such as IFN-alpha/beta, DDX58/RIG-I, TNFSF10/TRAIL, OAS1/2, PIAS1/GBP, EIF2AK2/PKR and RSAD2/viperin; antibacterial response, such as NOS2/INOS; anti-proliferative response, such as p53/TP53, LOX and CDKN1A; apoptosis, such as BBC3/PUMA, CASP1, CASP7 and CASP8; immune response, such as IL7, IL12A/B and IL15, PTGS2/COX2 and CYBB; DNA damage responses and DNA repair, such as POLQ/POLH; MHC class I expression, such as TAP1, PSMB9/LMP2, PSME1/PA28A, PSME2/PA28B and B2M and MHC class II expression, such as CIITA. Represses genes involved in anti-proliferative response, such as BIRC5/survivin, CCNB1, CCNE1, CDK1, CDK2 and CDK4 and in immune response, such as FOXP3, IL4, ANXA2 and TLR4. Stimulates p53/TP53-dependent transcription through enhanced recruitment of EP300 leading to increased acetylation of p53/TP53. Plays an important role in immune response directly affecting NK maturation and activity, macrophage production of IL12, Th1 development and maturation of CD8+ T-cells. Also implicated in the differentiation and maturation of dendritic cells and in the suppression of regulatory T (Treg) cells development. Acts as a tumor suppressor and plays a role not only in antagonism of tumor cell growth but also in stimulating an immune response against tumor cells.

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002250 adaptive immune response
GO:0002521 leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002755 MyD88-dependent toll-like receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002819 regulation of adaptive immune response
GO:0007050 cell cycle arrest
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0009612 response to mechanical stimulus
GO:0009615 response to virus
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0031349 positive regulation of defense response
GO:0032479 regulation of type I interferon production
GO:0032481 positive regulation of type I interferon production
GO:0032606 type I interferon production
GO:0032608 interferon-beta production
GO:0032615 interleukin-12 production
GO:0032648 regulation of interferon-beta production
GO:0032655 regulation of interleukin-12 production
GO:0032728 positive regulation of interferon-beta production
GO:0032735 positive regulation of interleukin-12 production
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0034121 regulation of toll-like receptor signaling pathway
GO:0034124 regulation of MyD88-dependent toll-like receptor signaling pathway
GO:0034340 response to type I interferon
GO:0034341 response to interferon-gamma
GO:0035456 response to interferon-beta
GO:0035458 cellular response to interferon-beta
GO:0035740 CD8-positive, alpha-beta T cell proliferation
GO:0036037 CD8-positive, alpha-beta T cell activation
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042090 interleukin-12 biosynthetic process
GO:0042098 T cell proliferation
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0043374 CD8-positive, alpha-beta T cell differentiation
GO:0045066 regulatory T cell differentiation
GO:0045075 regulation of interleukin-12 biosynthetic process
GO:0045084 positive regulation of interleukin-12 biosynthetic process
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045580 regulation of T cell differentiation
GO:0045581 negative regulation of T cell differentiation
GO:0045589 regulation of regulatory T cell differentiation
GO:0045590 negative regulation of regulatory T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045620 negative regulation of lymphocyte differentiation
GO:0045786 negative regulation of cell cycle
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046633 alpha-beta T cell proliferation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046640 regulation of alpha-beta T cell proliferation
GO:0046651 lymphocyte proliferation
GO:0050670 regulation of lymphocyte proliferation
GO:0050817 coagulation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0050878 regulation of body fluid levels
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051607 defense response to virus
GO:0060333 interferon-gamma-mediated signaling pathway
GO:0060337 type I interferon signaling pathway
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0071214 cellular response to abiotic stimulus
GO:0071260 cellular response to mechanical stimulus
GO:0071346 cellular response to interferon-gamma
GO:0071357 cellular response to type I interferon
GO:0071496 cellular response to external stimulus
GO:0071593 lymphocyte aggregation
GO:0098542 defense response to other organism
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:2000564 regulation of CD8-positive, alpha-beta T cell proliferation
GO:2001185 regulation of CD8-positive, alpha-beta T cell activation
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0044454 nuclear chromosome part
> KEGG and Reactome Pathway
 
KEGG hsa04917 Prolactin signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-913531: Interferon Signaling
R-HSA-909733: Interferon alpha/beta signaling
R-HSA-877300: Interferon gamma signaling
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
R-HSA-933541: TRAF6 mediated IRF7 activation
Summary
SymbolIRF1
Nameinterferon regulatory factor 1
Aliases MAR; interferon regulatory factor-1; IRF-1; interferon regulatory factor 1 isoform +I9; interferon regulator ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IRF1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IRF1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
10702232Cervical carcinomaPromote immunityInactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. Transient co-expression of E7 significantly inhibits the IRF-1-mediated activation of IFN-beta promoter in NIH-3T3 cells. These results suggest that HPV E7 interferes with the transactivation function of IRF-1 by recruiting HDAC to the promoter.
29090321Hepatocellular CarcinomaInhibit immunity (T cell function)In the present study, we asked whether TNF-α can promote the expression of B7-H1 induced by IFN-γ in HCC cells. We found that JAK/STAT1/IRF1 was the primary pathway responsible for induction of B7-H1 expression by IFN-γ in human HCC cell lines. TNF-α and IFN-γ synergistically induced the expression of B7-H1 in the HCC cells. Moreover, the mechanism of the synergy was that TNF-α enhanced IFN-γ signaling by upregulating the expression of IFN-γ receptors.
29628419melanoma; squamous Cell CarcinomaPromote immunity (T cell function); increase the efficacy of immunotherapyWe identified reduced levels of IRF1 and CXCL10 immunostimulatory molecules in highly glycolytic melanoma cells.
27923823Nasopharyngeal CarcinomaInhibit immunity; immunotherapy targetbortezomib, a proteasomal inhibitor, inhibited the pathways leading to STAT1 and IRF-1 activation, both of which are necessary for IDO expression.
21964766MelanomaPromote immunityWhole genome transcriptional analysis clearly indicate that regression of melanoma metastases is due to an acute immune rejection mediated by the upregulation of genes involved in antigen presentation and interferon mediated response (STAT-1/IRF-1) in all the regressing metastases from both patients.
21900395colon carcinomaPromote immunityMechanistic investigations revealed that IRF-1-induced NK cell cytotoxicity was independent of perforin and granzyme B but dependent on the NK cell activating receptor DNAM-1. Taken together, our findings establish IRF-1 as an essential mediator of the cross-talk between tumor cells and NK cells that mediate immune surveillance in the metastatic niche
Summary
SymbolIRF1
Nameinterferon regulatory factor 1
Aliases MAR; interferon regulatory factor-1; IRF-1; interferon regulatory factor 1 isoform +I9; interferon regulator ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IRF1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.72; FDR: 0.02000 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 8.14; FDR: 0.000 Resistant to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 8.50; FDR: 0.000 Resistant to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolIRF1
Nameinterferon regulatory factor 1
Aliases MAR; interferon regulatory factor-1; IRF-1; interferon regulatory factor 1 isoform +I9; interferon regulator ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IRF1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0250.961
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0170.993
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0610.967
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6950.204
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2890.885
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.2190.664
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6730.16
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9790.497
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2960.859
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.5150.434
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4810.621
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.230.073
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IRF1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIRF1
Nameinterferon regulatory factor 1
Aliases MAR; interferon regulatory factor-1; IRF-1; interferon regulatory factor 1 isoform +I9; interferon regulator ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IRF1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIRF1
Nameinterferon regulatory factor 1
Aliases MAR; interferon regulatory factor-1; IRF-1; interferon regulatory factor 1 isoform +I9; interferon regulator ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IRF1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IRF1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIRF1
Nameinterferon regulatory factor 1
Aliases MAR; interferon regulatory factor-1; IRF-1; interferon regulatory factor 1 isoform +I9; interferon regulator ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IRF1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIRF1
Nameinterferon regulatory factor 1
Aliases MAR; interferon regulatory factor-1; IRF-1; interferon regulatory factor 1 isoform +I9; interferon regulator ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IRF1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIRF1
Nameinterferon regulatory factor 1
Aliases MAR; interferon regulatory factor-1; IRF-1; interferon regulatory factor 1 isoform +I9; interferon regulator ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IRF1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIRF1
Nameinterferon regulatory factor 1
Aliases MAR; interferon regulatory factor-1; IRF-1; interferon regulatory factor 1 isoform +I9; interferon regulator ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IRF1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.